We are live on ! Find out more
FSTX

F-star Therapeutics, Inc. Common Stock

Delisted

FSTX was delisted on the 8th of March, 2023.

52 hedge funds and large institutions have $52.9M invested in F-star Therapeutics, Inc. Common Stock in 2018 Q2 according to their latest regulatory filings, with 20 funds opening new positions, 15 increasing their positions, 5 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

200% more repeat investments, than reductions

Existing positions increased: 15 | Existing positions reduced: 5

186% more first-time investments, than exits

New positions opened: 20 | Existing positions closed: 7

33% more funds holding

Funds holding: 3952 (+13)

10% less capital invested

Capital invested by funds: $59M → $52.9M (-$6.09M)

Holders
52
Holders Change
+13
Holders Change %
+33.33%
% of All Funds
1.19%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
20
Increased
15
Reduced
5
Closed
7
Calls
$2.37M
Puts
Net Calls
+$2.37M
Net Calls Change
-$706K
Name Holding Trade Value Shares
Change
Change in
Stake
MAM
51
Meeder Asset Management
Ohio
$1.64K +$1.94K +35 New
Bank of Montreal
52
Bank of Montreal
Ontario, Canada
$1K +$1.11K +20 New
Millennium Management
53
Millennium Management
New York
-$1.41M -22,916 Closed
HCM
54
Highbridge Capital Management
New York
-$615K -10,000 Closed
CM
55
Crestline Management
Texas
-$249K -4,055 Closed
WSFS
56
Wilmington Savings Fund Society
Delaware
-$215K -3,500 Closed
BCM
57
BlueCrest Capital Management
Jersey
-$189K -3,069 Closed
VF
58
Virtu Financial
New York
-$179K -2,911 Closed
TRCT
59
Tower Research Capital (TRC)
New York
-$4K -61 Closed

FSTX Hedge Fund Activity: Q2 2018 in Review

52 of the 4,369 institutional investors tracked by Wall St. Rank reported a position in F-star Therapeutics, Inc. Common Stock (FSTX) for Q2 2018, worth a combined $52.9M — down 10% from $59M a quarter earlier.

Buyers outnumbered sellers: 20 funds opened new FSTX positions and 7 closed out — a net gain of 13 holders — while 15 added to existing stakes and 5 trimmed.

The largest buyer was BlackRock, adding an estimated $6.28M. The largest seller was Alyeska Investment Group, cutting an estimated $2.14M.

  • 52 institutional investors held F-star Therapeutics, Inc. Common Stock (FSTX) as of Q2 2018, up from 39 in Q1 2018.
  • Funds reported $52.9M of F-star Therapeutics, Inc. Common Stock stock for Q2 2018, down 10% quarter-over-quarter.
  • 20 funds opened new F-star Therapeutics, Inc. Common Stock positions in Q2 2018 and 7 closed out, a net change of +13 holders.
  • The largest F-star Therapeutics, Inc. Common Stock buyer in Q2 2018 was BlackRock, an estimated $6.28M added.
  • The largest F-star Therapeutics, Inc. Common Stock seller in Q2 2018 was Alyeska Investment Group, an estimated $2.14M sold.

Based on aggregated 13F filings for Q2 2018.